Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide

• DOI: 10.1126/science.1204117
• Publication Date: 2011-07-21T18:49:01Z
• Authors: Chyuan-Chuan Wu; Tsai-Kun Li; Lynn Farh; Li-Ying Lin; Te-Sheng Lin; Yu-Jen Yu; Tien-Jui Yen; Chia-Wang Chiang; Nei-Li Chan
• Keywords: Models, Molecular; 0301 basic medicine; alpha; perspective; 612; chemotherapy; Crystallography, X-Ray; resistance; Structure-Activity Relationship; 03 medical and health sciences; substituents; Catalytic Domain; cancer; Humans; Topoisomerase II Inhibitors; cleavage; Protein Structure, Quaternary; Base Pairing; Etoposide; DNA; dna topoisomerases; Protein Structure, Tertiary; 3. Good health; DNA-Binding Proteins; enzyme; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Mutation; beta; Mutant Proteins; Protein Multimerization

Inhibition of an enzyme that alters DNA topology with an anticancer agent should facilitate development of better cancer drugs.